|4Jun 25, 7:16 PM ET

Palmetto Partners, Ltd. 4

4 · XERIS PHARMACEUTICALS INC · Filed Jun 25, 2018

Insider Transaction Report

Form 4
Period: 2018-06-25
Transactions
  • Conversion

    Common Stock

    2018-06-25+930,383930,383 total
  • Conversion

    Common Stock

    2018-06-25+581,9921,512,375 total
  • Conversion

    Common Stock

    2018-06-25+447,6861,960,061 total
  • Purchase

    Common Stock

    2018-06-25$15.00/sh+150,000$2,250,0002,110,061 total
  • Conversion

    Series B Preferred Stock

    2018-06-25797,3840 total
    Common Stock (447,686 underlying)
  • Conversion

    Series A Preferred Stock

    2018-06-251,657,1250 total
    Common Stock (930,383 underlying)
  • Conversion

    Series B Preferred Stock

    2018-06-251,036,5990 total
    Common Stock (581,992 underlying)
Footnotes (4)
  • [F1]The securities are owned by Palmetto Partners, 2014, LP, who is a member of a group with Palmetto Partners, Ltd. and Palmetto Partners 2015, LP.
  • [F2]Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis, at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date.
  • [F3]The securities are owned by Palmetto Partners 2015, LP, who is a member of a group with Palmetto Partners, Ltd. and Palmetto Partners 2014, LP.
  • [F4]The securities are owned by Palmetto Partners, Ltd., who is a member of a group with Palmetto Partners 2014, LP and Palmetto Partners 2015, LP.

Documents

1 file
  • 4
    edgar.xmlPrimary

    PRIMARY DOCUMENT